P185
Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South AfricaPreexposure chemoprophylaxis for HIV prevention in men who have sex with menCost-effectiveness of highly active antiretroviral therapy in South Africa.Tuberculosis vaccines and prevention of infectionMobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review.The impact of mass media interventions on tuberculosis awareness, health-seeking behaviour and health service utilisation: a systematic review protocol.Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methodsScreening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective studyRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirPoint-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysisLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Reimagining HIV service delivery: the role of differentiated care from prevention to suppression.Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.Decreasing household contribution to TB transmission with age: a retrospective geographic analysis of young people in a South African townshipShared air: a renewed focus on ventilation for the prevention of tuberculosis transmission.Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Induction of ER stress in macrophages of tuberculosis granulomas.Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients.Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa.Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking systemForce of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study.Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.Factors affecting tuberculosis strain success over 10 years in a high TB- and HIV-burdened community.Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism.High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa.HIV risk and associations of HIV infection among men who have sex with men in peri-urban Cape Town, South Africa.Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status.Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trialsChildhood tuberculosis infection and disease: a spatial and temporal transmission analysis in a South African township.Molecular epidemiology of Mycobacterium tuberculosis in a South African community with high HIV prevalence.Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice.Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa.Stochastic variation in network epidemic models: implications for the design of community level HIV prevention trialsImpact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011)Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria
P50
Q21261534-4076115D-6BD3-4FD3-818E-F819D30B0189Q24612082-14091C38-5E5A-4DB7-96FE-E8AFF7275825Q24814698-A7D5B133-5D6D-4931-B9AD-E3F64DCDEC84Q26782022-492F4645-6CA8-45D0-88D0-D3AD9F31E282Q26824866-29B66341-DDB1-4297-9484-A74CBDFD8559Q26829087-3BC919B6-814F-42CB-AC54-7883A18A7A49Q27313352-41D31BA8-6512-46F7-860F-EE3DA5EE0E94Q28478065-94B4CA48-FE72-4CBA-9F2A-014BFDC01FFAQ28479309-8D0539C6-3725-41D3-A152-B47605862E90Q28533242-957D9320-009C-4F80-A2E0-0A20644DBD4FQ28543954-AB1B0C37-9DEF-41A7-96C6-4073BAF5A466Q28654629-CC754D9B-EE03-4FB2-A8F4-190BBEA3AB5FQ28741673-604A0EC0-F57A-4B55-A49E-7BBD9106079DQ30151558-47E49C06-F929-42A9-8D27-717EA92E1F6EQ30228870-53339632-7EE7-4152-BF33-E0124EE3EE76Q33237178-9967EEB0-EDF2-4EC4-BF69-DD5ED4BA9445Q33574194-08DFF929-6FD6-4D07-87C0-E446E5D0C08CQ33577939-1453CFF7-1E90-4205-872A-8C3979FBC0B0Q33629439-C258A19D-5807-4374-8C55-89BC79A03007Q33697646-46096C7A-D5C6-41BF-A510-70665DC7A7C8Q33716960-3CE636AB-1D3E-463A-B384-B0FDE4C5C179Q33745099-B1B30E44-E2F9-4A6D-8B4F-AD1CCD70AC5BQ33746982-8A21DB47-24B5-4180-9D9F-AECD2A0ACA34Q33919181-34116CD2-B748-4893-8301-626109F275C7Q33999615-98EC6B3A-B0AB-4429-890B-58F1E5B7638BQ34001209-10675D1A-DE4A-4065-B451-41DA9E9FA7C7Q34030735-7EEFB8EF-AEB0-4ECA-96DD-EEB1F463D6E3Q34033091-4CF8670C-A0DC-439E-90C7-A74DFA3D8D86Q34039494-2C70F50C-8465-4D97-B6D3-5EDAC7C09B71Q34041128-CFD59FF0-5937-410E-8BC0-399B83273F40Q34053275-189BB08F-733A-4ABF-AC7C-56C368042DF8Q34055991-23EB1326-5EB5-45EA-A360-B6B56630E2F3Q34099909-3E38602C-E0E3-42F5-ABB5-41CEF822E008Q34100685-7257E695-A05F-4902-86C3-2D1F88CF9ADDQ34102202-9304590F-8A71-4A79-9926-440751381663Q34120690-6D9FD764-58FB-4D3B-88D7-3346B345BD2AQ34138223-BFC0D67D-D8B7-4578-8811-700BD9F8A92BQ34143495-27B573E7-E4C5-4EF4-B739-D6E682D3C345Q34169277-8D51745D-A889-4E94-824E-2C1C1799F9F7Q34173643-32705231-B536-44BF-B102-3B38A0DDBFCA
P50
description
Zimbabwaans onderzoekster (1962-)
@nl
Zimbabwean physician & academic
@en
médecin, immunologiste et professeur de médecine zimbabwéenne
@fr
médica zimbabuana
@ast
հետազոտող
@hy
name
Linda-Gail Bekker
@ast
Linda-Gail Bekker
@de
Linda-Gail Bekker
@en
Linda-Gail Bekker
@es
Linda-Gail Bekker
@fr
Linda-Gail Bekker
@ga
Linda-Gail Bekker
@nl
Linda-Gail Bekker
@pt
Linda-Gail Bekker
@sl
type
label
Linda-Gail Bekker
@ast
Linda-Gail Bekker
@de
Linda-Gail Bekker
@en
Linda-Gail Bekker
@es
Linda-Gail Bekker
@fr
Linda-Gail Bekker
@ga
Linda-Gail Bekker
@nl
Linda-Gail Bekker
@pt
Linda-Gail Bekker
@sl
altLabel
Bekker L
@en
Bekker L-G
@en
Bekker L. G.
@en
Bekker L.
@en
Bekker L.-G.
@en
Bekker LG
@en
Bekker
@en
L Bekker
@en
L G Bekker
@en
L-G Bekker
@en
prefLabel
Linda-Gail Bekker
@ast
Linda-Gail Bekker
@de
Linda-Gail Bekker
@en
Linda-Gail Bekker
@es
Linda-Gail Bekker
@fr
Linda-Gail Bekker
@ga
Linda-Gail Bekker
@nl
Linda-Gail Bekker
@pt
Linda-Gail Bekker
@sl
P106
P101
P103
P184
P19
P1960
kK1V_ZoAAAAJ
P2002
LindaGailBekker
P2031
1987-01-01T00:00:00Z
P21
P27
P31
P39
P496
0000-0002-0755-4386
P569
1962-01-01T00:00:00Z